Cary Street Partners Financial LLC Purchases New Holdings in The Clorox Company (NYSE:CLX)

Cary Street Partners Financial LLC acquired a new position in shares of The Clorox Company (NYSE:CLX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,958 shares of the company’s stock, valued at approximately $318,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CLX. Balyasny Asset Management L.P. grew its holdings in shares of Clorox by 28.7% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,421,909 shares of the company’s stock worth $230,932,000 after purchasing an additional 316,688 shares in the last quarter. Baker Avenue Asset Management LP increased its holdings in Clorox by 23.8% in the 4th quarter. Baker Avenue Asset Management LP now owns 1,553 shares of the company’s stock valued at $252,000 after buying an additional 299 shares during the period. Benjamin Edwards Inc. raised its position in shares of Clorox by 0.8% in the 4th quarter. Benjamin Edwards Inc. now owns 63,894 shares of the company’s stock valued at $10,381,000 after buying an additional 526 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Clorox by 20.4% during the 4th quarter. BNP Paribas Financial Markets now owns 210,317 shares of the company’s stock worth $34,158,000 after acquiring an additional 35,570 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Clorox by 14.8% during the 4th quarter. Ameriprise Financial Inc. now owns 245,686 shares of the company’s stock worth $39,902,000 after acquiring an additional 31,624 shares in the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Trading Down 2.2 %

Shares of CLX stock opened at $134.79 on Friday. The Clorox Company has a 1-year low of $127.60 and a 1-year high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The stock has a market cap of $16.60 billion, a price-to-earnings ratio of 36.83, a PEG ratio of 2.62 and a beta of 0.60. The stock has a 50-day moving average of $142.37 and a 200-day moving average of $154.07.

Clorox (NYSE:CLX) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter in the previous year, the business posted $1.71 EPS. The firm’s revenue for the quarter was down 8.0% compared to the same quarter last year. On average, equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd were issued a dividend of $1.22 per share. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.62%. Clorox’s payout ratio is currently 87.61%.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at $546,280. This trade represents a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CLX shares. JPMorgan Chase & Co. lowered their price objective on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on Clorox from $145.00 to $142.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. DA Davidson lowered their target price on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Citigroup reduced their price target on shares of Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a research note on Monday, April 14th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $150.00 price objective on shares of Clorox in a research report on Thursday, January 30th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.